XT
AARD

XTX Topco’s Aardvark Therapeutics AARD Stock Holding History

XTX Topco’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$115K Sell
19,888
-27
-0.1% -$126 ﹤0.01% 3485
2026
Q1 		$75.1K Sell
19,915
-5,633
-22% -$58.4K ﹤0.01% 3198
2025
Q4 		$335K Buy
+25,548
New +$319K 0.01% 1969

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

XTX Topco's AARD Position: Q2 2026 in Review

XTX Topco reduced its Aardvark Therapeutics (AARD) stake by 0.14% in Q2 2026, selling an estimated $126 and leaving 19,888 shares worth $115K. The position accounts for ﹤0.01% of the portfolio, ranked #3485.

XTX Topco first reported a position in AARD in Q4 2025 and has held it in 3 quarters since. The position peaked at $335K in Q4 2025. 71 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

  • XTX Topco held 19,888 shares of Aardvark Therapeutics worth $115K as of Q2 2026.
  • XTX Topco sold 27 Aardvark Therapeutics shares in Q2 2026, an estimated $126.
  • Aardvark Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q2 2026, its #3485 holding.
  • XTX Topco first reported a position in Aardvark Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • XTX Topco's Aardvark Therapeutics position peaked at $335K in Q4 2025.
  • 71 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.